Cargando…
Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma
Osteosarcoma is the most frequently occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common. Eribulin is a synthetic microtubule inhibitor that has demonstrated activity in preclinical osteosarcoma models. The effects of eribulin were evaluated in two human os...
Autores principales: | Sampson, Valerie B., Vetter, Nancy S., Zhang, Wendong, Patil, Pratima U., Mason, Robert W., George, Erika, Gorlick, Richard, Kolb, Edward A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349938/ https://www.ncbi.nlm.nih.gov/pubmed/27863409 http://dx.doi.org/10.18632/oncotarget.13358 |
Ejemplares similares
-
A Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for Osteosarcoma
por: Sampson, Valerie B., et al.
Publicado: (2013) -
MicroRNAs and Potential Targets in Osteosarcoma: Review
por: Sampson, Valerie B., et al.
Publicado: (2015) -
p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma
por: Currier, Arthur W., et al.
Publicado: (2019) -
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023) -
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
por: Jernigan, Finith, et al.
Publicado: (2021)